199 related articles for article (PubMed ID: 29758280)
1. Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma.
Zhang XH; Nam S; Wu J; Chen CH; Liu X; Li H; McKeithan T; Gong Q; Chan WC; Yin HH; Yuan YC; Pillai R; Querfeld C; Horne D; Chen Y; Rosen ST
J Invest Dermatol; 2018 Nov; 138(11):2377-2387. PubMed ID: 29758280
[TBL] [Abstract][Full Text] [Related]
2. Targeting the non-ATP-binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T-cell lymphoma (CTCL).
Zhang XH; Chen CH; Li H; Hsiang J; Wu X; Hu W; Horne D; Nam S; Shively J; Rosen ST
FEBS Lett; 2021 Oct; 595(20):2570-2592. PubMed ID: 34455585
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
4. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
5. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
6. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
Wu CH; Yang CY; Wang L; Gao HX; Rakhshandehroo T; Afghani S; Pincus L; Balassanian R; Rubenstein J; Gill R; Bandyopadhyay S; McCormick F; Moasser M; Ai WZ
J Invest Dermatol; 2021 Feb; 141(2):364-373. PubMed ID: 32603749
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma.
Bresin A; Cristofoletti C; Caprini E; Cantonetti M; Monopoli A; Russo G; Narducci MG
J Invest Dermatol; 2020 May; 140(5):1045-1053.e6. PubMed ID: 31682844
[TBL] [Abstract][Full Text] [Related]
9. Targeting Phosphorylation of p21-activated Kinase 1 at Thr423 Induces Cell Cycle Arrest and Apoptosis in Cutaneous T-cell Lymphoma Cells.
Wang Y; Li W; Zhang Q; Gu X; He X; Men Y; Zhang C
Acta Derm Venereol; 2019 Oct; 99(11):1022-1028. PubMed ID: 31304555
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
12. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
13. p38γ MAPK is required for inflammation-associated colon tumorigenesis.
Yin N; Qi X; Tsai S; Lu Y; Basir Z; Oshima K; Thomas JP; Myers CR; Stoner G; Chen G
Oncogene; 2016 Feb; 35(8):1039-48. PubMed ID: 25961922
[TBL] [Abstract][Full Text] [Related]
14. p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis.
Wang F; Qi XM; Wertz R; Mortensen M; Hagen C; Evans J; Sheinin Y; James M; Liu P; Tsai S; Thomas J; Mackinnon A; Dwinell M; Myers CR; Bartrons Bach R; Fu L; Chen G
Cancer Res; 2020 Aug; 80(16):3251-3264. PubMed ID: 32580961
[TBL] [Abstract][Full Text] [Related]
15. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
16. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma.
Huang Y; Su MW; Jiang X; Zhou Y
Blood; 2015 Feb; 125(9):1435-43. PubMed ID: 25548321
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
[TBL] [Abstract][Full Text] [Related]
18. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
19. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
[TBL] [Abstract][Full Text] [Related]
20. p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer.
Meng F; Zhang H; Liu G; Kreike B; Chen W; Sethi S; Miller FR; Wu G
Neoplasia; 2011 May; 13(5):472-82. PubMed ID: 21532888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
